New BARDA Awards: Esperovax, Inc. USA Produc
Post# of 36537
(Total Views: 526)
Posted On: 08/26/2020 3:25:50 PM
New BARDA Awards:
Esperovax, Inc. USA
Product Name: Egress RD mRNA Oral Cellular Vaccine Delivery Technology
Description:
An oral immunization for COVID-19 involving delivery of enveloped virus like particles (eVLPs) by capsule to the gut that will induce immune protection against disease.
Unique Impact:
This technology aims to provide a cost-effective technological innovation that improves immunization uptake, coverage, compliance and preparedness, with the potential for self-administration
Base Award Amount: $606,780.00 (July 27, 2020)
Cost Share: Yes
University of Connecticut USA
Product Name: Single-Administration Microneedle Skin Patch for Pandemic Vaccine
Description:
An easy-to-use vaccine-delivery microneedle (MN) patch (i.e., Micro Array Patch) that will contain the spike protein (the S-protein on the shell of COVID-19 virus) and be programmed to automatically deliver this S-protein (as an antigen against COVID-19) into the skin.
Unique Impact:
This technology has the potential for mass distribution of self-administered immunizations that rival or potentially surpass the effectiveness of an immunization delivered via traditional needle and syringe.
Base Award Amount: $432,990.00 (August 17, 2020)
Cost Share: Yes
Vaxess Technologies, Inc. USA
Product Name: MIMIX-COVID Pre-fusion Spike Protein Micro Array Patch
Description:
MIMIX Vaccine Patch Development and Scaling of shelf-stable, self-applied, single-dose Micro Array Patch (MAP) technology
Unique Impact:
This technology could open the profound potential for large-scale distribution of self-administered immunizations that rival or potentially surpass the effectiveness of an immunization delivered via traditional needle and syringe.
Base Award Amount: $749,000.00 (August 9, 2020)
Cost Share: Yes
Verndari, Inc. USA
Product Name: VaxiPatch™ Complete Vaccination Kit
Description:
SARS-CoV-2 Recombinant Spike Receptor Binding Domain protein administered via Micro Array Patch (MAP) Technology
Unique Impact:
This technology aims to provide a cost-effective technological innovation that improves immunization uptake, coverage, compliance and preparedness, with the potential for self-administration.
Base Award Amount: $698,215.00 (July 23, 2020)
Cost Share: Yes
Esperovax, Inc. USA
Product Name: Egress RD mRNA Oral Cellular Vaccine Delivery Technology
Description:
An oral immunization for COVID-19 involving delivery of enveloped virus like particles (eVLPs) by capsule to the gut that will induce immune protection against disease.
Unique Impact:
This technology aims to provide a cost-effective technological innovation that improves immunization uptake, coverage, compliance and preparedness, with the potential for self-administration
Base Award Amount: $606,780.00 (July 27, 2020)
Cost Share: Yes
University of Connecticut USA
Product Name: Single-Administration Microneedle Skin Patch for Pandemic Vaccine
Description:
An easy-to-use vaccine-delivery microneedle (MN) patch (i.e., Micro Array Patch) that will contain the spike protein (the S-protein on the shell of COVID-19 virus) and be programmed to automatically deliver this S-protein (as an antigen against COVID-19) into the skin.
Unique Impact:
This technology has the potential for mass distribution of self-administered immunizations that rival or potentially surpass the effectiveness of an immunization delivered via traditional needle and syringe.
Base Award Amount: $432,990.00 (August 17, 2020)
Cost Share: Yes
Vaxess Technologies, Inc. USA
Product Name: MIMIX-COVID Pre-fusion Spike Protein Micro Array Patch
Description:
MIMIX Vaccine Patch Development and Scaling of shelf-stable, self-applied, single-dose Micro Array Patch (MAP) technology
Unique Impact:
This technology could open the profound potential for large-scale distribution of self-administered immunizations that rival or potentially surpass the effectiveness of an immunization delivered via traditional needle and syringe.
Base Award Amount: $749,000.00 (August 9, 2020)
Cost Share: Yes
Verndari, Inc. USA
Product Name: VaxiPatch™ Complete Vaccination Kit
Description:
SARS-CoV-2 Recombinant Spike Receptor Binding Domain protein administered via Micro Array Patch (MAP) Technology
Unique Impact:
This technology aims to provide a cost-effective technological innovation that improves immunization uptake, coverage, compliance and preparedness, with the potential for self-administration.
Base Award Amount: $698,215.00 (July 23, 2020)
Cost Share: Yes
(0)
(0)Generex Biotechnology Corp. (GNBTQ) Stock Research Links
Scroll down for more posts ▼